Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Notes Payables (2021 - 2023)

Indivior Pharmaceuticals (INDV) has 2 years of Notes Payables data on record, last reported at $3.0 million in Q4 2022.

  • For Q4 2022, Notes Payables changed 0.0% year-over-year to $3.0 million; the TTM value through Dec 2022 reached $3.0 million, changed 0.0%, while the annual FY2022 figure was $3.0 million, 0.0% changed from the prior year.
  • Notes Payables reached $3.0 million in Q4 2022 per INDV's latest filing, roughly flat from $3.0 million in the prior quarter.
  • Across five years, Notes Payables topped out at $3.0 million in Q4 2021 and bottomed at $3.0 million in Q4 2021.